GARY MILLER: Open Payments
NPI 1770503336 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$243 in 12 payments from 8 companies in 2025. Trend: 2023 $299 · 2024 $832 · 2025 $243
Food & beverage: $243
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Neurocrine BioSciences, Inc. | 2 | $47 |
| Janssen Pharmaceuticals, Inc | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Dentsply Sirona Inc | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
| Corium, LLC | 1 | $3 |
Products named: COBENFY, INGREZZA, REXULTI, INVEGA SUSTENNA, AUSTEDO XR, X-SMART, ABILIFY MAINTENA, CAPLYTA.
Industry payments across TX — which companies pay providers there.
